The safety analysis was based on 44 selumetinib and 43 controls, and the efficacy analysis on 43 and 40 patients, respectively.
The majority of patients, or 88%, were current or former smokers, roughly half had a WHO performance status 0, and 82% had adenocarcinoma histology. Their median age was 59 years.
The study was sponsored by AstraZeneca. Dr. Jänne reported a consultant/advisory role with AstraZeneca; several of his coauthors reported financial relationships with firms including employment or stock ownership with AstraZeneca. Dr. Neal reported research funding from Genentech.